Gene Therapy Strategy for Tumour Hypoxia by Harada, Hiroshi
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
11 
Gene Therapy Strategy for Tumour Hypoxia 
Hiroshi Harada 
Group of Radiation and Tumour Biology, 
Career-Path Promotion Unit for Young Life Scientists,  
Kyoto University 
Japan 
1. Introduction 
A characteristic feature of solid tumours is the presence of cells under very low oxygen 
tensions, hypoxia. These cells, so called hypoxic tumour cells, express a transcription factor, 
hypoxia-inducible factor 1 (HIF-1), which induces the expression of more than one hundred 
genes related to angiogenesis, invasion, metastasis, and resistance to conventional 
treatments such as chemotherapy and radiotherapy. However, because hypoxia is unique to 
locally advanced malignant tumours, it provides the opportunity to develop tumour-
specific targeting strategies. Such an approach has been applied to gene therapy; for 
example, hypoxia-activated gene therapy using HIF-1-dependent promoters resulted in the 
selective expression of therapeutic genes and anti-tumour effects with minimum side effects 
in normal tissues. Here, I review recent advances in the development of cancer gene therapy 
strategies targeting hypoxic/HIF-1-active tumour cells. 
2. A tumour-specific microenvironment, hypoxia, as a therapeutic target 
Most human tumours are highly heterogeneous and involve diverse microenvironments. A 
typical microenvironment seen in solid tumours is hypoxia, low-oxygen conditions under 
physiological level (Thomlinson & Gray, 1955; Vaupel, Kallinowski, & Okunieff, 1989). 
Tumour hypoxia is a concern in cancer therapy because it increases the metastatic and 
angiogenic potential of cancer cells (Erler et al., 2006; Forsythe et al., 1996; Yang et al., 2008) 
and can render cancer cells resistant to radiation and chemotherapy (Brown & Wilson, 2004; 
Teicher, 1994; Thomlinson & Gray, 1955). 
2.1 What is tumour hypoxia and how does it occur in solid tumours? 
A typical feature of cancer cells is an extraordinarily accelerated proliferation caused by the 
activation of oncogenes and/or disruption of tumour suppressor genes (Hanahan & 
Weinberg, 2000). It leads to an imbalance in the supply and consumption of O2 in a solid 
tumour. This disequilibrium along with the inadequate diffusion of molecular oxygen can 
cause a dynamic gradient of O2 content in a solid tumour (Thomlinson & Gray, 1955; Vaupel 
et al., 1989). Tumour cells proliferate and grow actively only if supplied with enough 
oxygen and nutrients from tumour blood vessels; therefore, malignant solid tumours grow 
as a conglomerate of so-called “tumour cords” in each of which a blood vessel is 
sequentially surrounded with well-oxygenated viable cells (normoxic cells), dormant cells 
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under low oxygen conditions (hypoxic cells), and dead cells (necrotic cells) Fig. 1(Hall, 
1994). Because of the distance that O2 can diffuse, hypoxic cells exist 70-100 µm from a 
tumour blood vessel in a tumour cord (Hall, 1994). Hypoxic conditions are usually defined 
as < 2% O2, and anoxic conditions (severe hypoxia) as < 0.02% O2. 
 
 
Fig. 1. Spatial relationship between blood vessels and hypoxia in a malignant solid tumour. 
Chronic hypoxic regions (red) exist 70-100 µm from tumour blood vessels. Acute/cycling 
hypoxia caused by fluctuations in tumour blood flow occurs proximal to tumour blood 
vessels. 
In addition to areas of chronic hypoxia, malignant tumours contain cancer cells which are 
temporally exposed to low oxygen conditions for minutes to hours and then reoxygenated 
(Brown, 1979). This phenomenon, called “acute hypoxia”, frequently reoccurs during 
tumour growth, leading to “cycling hypoxia”. The occurrence of acute and cycling hypoxia 
is attributed to the fact that tumour blood vessels are quite immature and tortuous; and 
therefore, tumour blood flow fluctuates dramatically during tumour growth (Brown & 
Wilson, 2004).  
2.2 Chemo-resistance of cancer cells under hypoxic conditions 
Cancer cells are known to become chemo-resistant in hypoxic regions of locally advanced 
solid tumours through multiple mechanisms (Kizaka-Kondoh, Inoue, Harada, & Hiraoka, 
2003; Teicher, 1994). First, because hypoxic regions occur far from functional vasculatures, 
the diffusion and delivery of most anticancer drugs are not extensive enough to have a 
cytotoxic effect (Durand, 1994; Hicks et al., 2006; Tannock, 1998). Second, the cytotoxicity of 
some anticancer drugs is known to depend on molecular oxygen. For example, bleomycin is 
reported to chelate metal ions, produce a pseudoenzyme that reacts with oxygen and 
www.intechopen.com
 Gene Therapy Strategy for Tumour Hypoxia 
 
187 
generates superoxide and hydroxide free radicals, and then cleave DNA. Therefore, the 
cytotoxic effect of the drug dramatically decreases in the absence of O2 (Batchelder, Wilson, 
Hay, & Denny, 1996; Teicher, Lazo, & Sartorelli, 1981). Third, alkylating agents and 
antimetabolites are also less effective under hypoxic conditions. These kinds of drugs are the 
most effective against highly proliferating cancer cells, and therefore, hypoxic tumour cells, 
which are known to be dormant/less proliferating, can tolerate them (Tannock, 1968). 
Fourth, hypoxia upregulates the expression of genes involved in drug resistance, including 
the gene for p-glycoprotein (Comerford et al., 2002; Wartenberg et al., 2003). Finally, there is 
evidence that hypoxia can enhance genetic instability in tumour cells (N. Chan et al., 2008), 
thus allowing a more rapid development of drug resistance. 
2.3 Radio-resistance of cancer cells under hypoxic conditions 
Ionizing radiation produces DNA damage, such as DNA double/single strand breaks, DNA 
base damage, and DNA-DNA and DNA-protein crosslinks (Hall, 1994). The presence or 
absence of molecular oxygen influences the damage and death of cancer cells (Brown & 
Wilson, 2004; Thomlinson & Gray, 1955). This phenomenon, the so-called oxygen effect, was 
first identified in 1912 with the observation that the skin reaction to a radium applicator 
dramatically decreased when the applicator was pushed tightly onto the skin and 
consequently decreased blood flow there. The breakthrough linking the effect of oxygen 
with radioresistance of cancer cells was made by Thomlinson and Gray in 1955 (Thomlinson 
& Gray, 1955). They proposed that oxygen levels decreased in a solid tumour through 
successive layers of cancer cells distal to blood vessels, and cancer cells a distance of about 
10 cell diameters from vessels are viable but radioresistant. Actually, cancer cells become 2-3 
times more radioresistant under hypoxic conditions than normoxic conditions (Brown & 
Wilson, 2004).  
The hypoxia-mediated radioresistance is attributed to both chemical and biological 
mechanisms. Ionizing radiation induces ionization in or close to the genomic DNA of target 
cells and produces radicals (Brown & Wilson, 2004). The DNA radicals are subjected to 
oxidation in the presence of oxygen, leading to fixation of the damage. In the absence of 
oxygen, however, the DNA radicals are reduced by compounds containing sulfhydryl 
groups (SH groups), which restore the DNA to its original form. Therefore, DNA damage, 
especially irreparable double stranded breaks, is significantly less severe in the absence of 
molecular oxygen. Biological mechanisms are also important. It has been elucidated that 
hypoxic stimuli trigger changes in both the “DNA damage repair pathway” (Bindra, 
Crosby, & Glazer, 2007) and the “cell death/survival signaling pathway”. Moreover, recent 
advances in molecular and cellular biology revealed an important role for a transcription 
factor, hypoxia-inducible factor 1 (HIF-1), in tumour radioresistance (see Section 3 for 
details) (Harada & Hiraoka, 2010).  
2.4 Increase in metastatic and angiogenic potential under hypoxic conditions  
In addition to mediating resistance to conventional treatments, hypoxia is known to increase 
the metastatic and angiogenic potential of tumour cells. Cancer patients with relatively more 
hypoxic regions have a tendency to suffer from distant metastasis as well as local recurrence 
regardless of whether the initial treatment is surgery or radiation therapy (Brizel et al., 
1996). Recent molecular biological analyses have revealed that hypoxia stimulates the 
expression of a number of genes involved in metastatic cascades, such as lysyl oxidase and 
the chemokine receptor, CXCR4, osteopoetin (D. A. Chan & Giaccia, 2007; Erler et al., 2006; 
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Rofstad, 2000). Also, cancer cells under hypoxic conditions trigger angiogenesis in order to 
improve surrounding conditions and obtain enough oxygen and nutrients for their survival 
(Folkman, 1971). HIF-1 is known to play a pivotal role in the hypoxia-mediated increase in 
both the metastatic and angiogenic potential of cancer cells. 
3. Hypoxia-inducible factor 1 (HIF-1) 
Molecular and cellular biological research has identified HIF-1 as an important transcription 
factor in hypoxia-mediated angiogenesis, metastasis, and resistance to chemo/radiotherapy. 
3.1 Regulation of HIF-1 expression and activity 
HIF-1 is a heterodimeric transcription factor composed of alpha (HIF-1α) and beta (HIF-
1β/ARNT) subunits (Wang, Jiang, Rue, & Semenza, 1995). Its hypoxia-dependent activity is 
mainly regulated through the stabilization and modification of the HIF-1α subunit (Fig. 2). 
 
 
Fig. 2. Molecular mechanism behind the activation of HIF-1 under Hypoxic conditions.  
The best-characterized regulatory mechanism is that modulating HIF-1α’s stability. Under 
well-oxygenated normoxic conditions, prolyl hydroxylation (by prolyl hydroxylases 
[PHDs]) and subsequent ubiquitination (by von-Hippel Lindau (VHL)-containing E3 
ubiquitin-protein ligase) of the oxygen-dependent degradation (ODD) domain of HIF-1α 
leads to rapid degradation of HIF-1α with a half life of 5-8 min. Consequently, HIF-1 is 
inactive under normoxic conditions (Berra, Roux, Richard, & Pouyssegur, 2001; Hirota & 
Semenza, 2005; Jaakkola et al., 2001; Maxwell et al., 1999; Semenza, 2001). On the other hand, 
under oxygen-deprived hypoxic conditions, HIF-1α becomes stable because oxygen-
www.intechopen.com
 Gene Therapy Strategy for Tumour Hypoxia 
 
189 
depletion directly decreases the PHDs’ activity (Jaakkola et al., 2001). Then, HIF-1α interacts 
with HIF-1β, forms a heterodimer, HIF-1 (Wang et al., 1995), binds to its cognate DNA 
sequence, the hypoxic-responsive element (HRE), and finally induces the expression of 
various genes related to angiogenesis, metastasis, glycolysis and so on (D. A. Chan & 
Giaccia, 2007; Erler et al., 2006; Forsythe et al., 1996; Kim, Gao, & Dang, 2007; Rofstad, 2000). 
In addition to the regulation of HIF-1α’s stability, another post-translational modification of 
HIF-1α is known to function in the regulation of the transactivational activity of HIF-1. 
Under normoxic conditions, factor inhibiting HIF-1 (FIH-1) becomes active and 
hydroxylates an asparagine residue (N803) of HIF-1α (Hirota & Semenza, 2005; Mahon, 
Hirota, & Semenza, 2001; Semenza, 2001). The asparaginyl hydroxylation blocks the 
interaction of HIF-1α with the transcriptional co-factor p300 and CBP, resulting in the 
suppression of HIF-1’s transactivational activity. Because oxygen is a substrate of FIH-1 as 
well as PHDs, HIF-1’s transactivational activity is restored under oxygen-deprived hypoxic 
conditions. 
3.2 Function of HIF-1 in cancer cells 
In cancer cells, HIF-1 plays pivotal roles in the adaptation to (metabolic reprograming), 
evasion from (invasion and metastasis), and improvement of (angiogenesis) severe hypoxic 
conditions (D. A. Chan & Giaccia, 2007; Erler et al., 2006; Forsythe et al., 1996; Semenza, 
2007, 2008). Concerning angiogenesis in locally advanced malignant tumours, an up-
regulation of HIF-1 activity caused by intratumoural hypoxia is associated with the 
overexpression of vascular endothelial growth factor (VEGF), a glycoprotein responsible for 
angiogenesis and vasculogenesis (Forsythe et al., 1996). Concerning the metabolic 
reprogramming of cancer cells, HIF-1 induces the expression of genes encoding glucose 
transporters and glycolytic enzymes to facilitate glycolysis (Semenza, 2009; Wood et al., 
1998). At the same time, HIF-1-dependent genes decrease both mitochondrial metabolism 
(Fukuda et al., 2007; Semenza, 2007) and mitochondrial mass (Semenza, 2008; H. Zhang et 
al., 2008). These functions of HIF-1 are responsible for both the efficient production of ATP 
even under oxygen-deprived conditions and the decrease in the cytotoxic reactive oxygen 
species (ROS) produced through incomplete oxidative phosphorylation under hypoxic 
conditions (Fukuda et al., 2007; Semenza, 2007, 2009). Concerning invasion and metastasis, 
HIF-1 is known to trigger various pathways including epithelial-mesenchymal transition 
(EMT) and expression of the Met protooncogene and lysyl oxidase, which function in 
tumour metastasis (Erler et al., 2006; Pennacchietti et al., 2003). 
3.3 Function of HIF-1 in tumour radioresistance 
Preclinical studies have found that inhibition of intratumour HIF-1 activity by a 
pharmacological HIF-1 inhibitor, YC-1, or by a dominant negative mutant of HIF-1α and the 
knockdown of HIF-1α expression by short hairpin RNA or short interfering RNA 
significantly delayed tumour growth after radiation (Harada et al., 2009; Moeller, Cao, Li, & 
Dewhirst, 2004; Moeller et al., 2005; X. Zhang et al., 2004). It was also confirmed through 
clinical studies that HIF-1α expression correlates with a poor prognosis after radiation 
therapy (Aebersold et al., 2001; Irie, Matsuo, & Nagata, 2004; Ishikawa et al., 2004). These 
results imply that HIF-1 has a certain biological function to increase tumour radioresistance. 
Actually, HIF-1-mediated radioresistance has been recently revealed: 1) radiation activates 
HIF-1 in a solid tumour, 2) HIF-1 induces the expression of VEGF, 3) VEGF protects 
endothelial cells from the cytotoxic effects of radiation, and 4) the radio-protected tumour 
www.intechopen.com
 Targets in Gene Therapy 
 
190 
blood vessels assure the supply of oxygen and nutrients to tumour cells and promote 
tumour growth (Harada et al., 2009; Moeller et al., 2004; Zeng et al., 2008). 
4. Development of gene therapy strategies targeting tumour hypoxia 
Because hypoxic/HIF-1-active cells are known to mediate tumour malignancy and 
resistance to conventional treatments, and because hypoxia has been recognized as a 
tumour-specific microenvironment, recent studies have tried to exploit hypoxic cells as 
targets for cancer therapy (Brown & Wilson, 2004; Harris, 2002; Semenza, 2003). Dachs et al. 
were the first to apply this concept to gene therapy (Dachs, Patterson, et al., 1997).  Since 
they demonstrated the effectiveness of hypoxia-specific gene therapy strategy using the 
HIF-1/HRE system, extensive efforts have been devoted to developing genetically 
engineered hypoxia-responsive promoters. 
4.1 Development of HIF-1-dependent promoters 
Various HREs, such as murin phosphoglycerate kinase-1 (PGK-1) HRE, human enolase 
(ENO) HRE, murin lactate dehydrogenase (mLDH-A) HRE, human erythropoietin (EPO) 
HRE, and human VEGF HRE, have been used to develop artificial hypoxia-responsive 
promoters (Table 1) (Binley, Iqball, Kingsman, Kingsman, & Naylor, 1999; Boast et al., 1999; 
Dachs, Patterson, et al., 1997; Harada et al., 2007; Rinsch et al., 1997; Shibata, Akiyama, 
Noda, Sasai, & Hiraoka, 1998; Shibata, Giaccia, & Brown, 2000). The number of HREs and 
combination with the basal promoter influence the hypoxia/HIF-1-responsiveness of each 
HRE-containing promoter (Table 1). 
Above all, the combination of five repeats of a HRE derived from the human VEGF 
promoter and the human cytomegarovirus (CMV) minimal promoter (mp), the so-called 
“the 5HRE promoter“, showed intense hypoxia-responsiveness and exhibited a more than 
500-fold increase in luciferase activity in response to hypoxic stimuli (Shibata et al., 2000). 
Moreover, the absolute level of luciferase activity from the 5HRE promoter under hypoxic 
conditions reached the same level as that from the constitutively active CMV-driven 
promoter under normoxic conditions (Shibata et al., 2000).  
However, the 5HRE promoter still has problems relating to the development of gene 
therapy. It shows a certain level of unwanted gene expression even when oxygen is 
available under normoxic conditions (Harada et al., 2007), which would cause high basal 
expression of therapeutic genes and result in side effects in well-oxygenated normal tissues. 
In order to decrease leakage under normoxic conditions, I and my colleagues came up with 
the idea of utilizing the ODD domain of HIF-1α. We fused the coding sequence of the ODD 
domain to that of luciferase, and inserted the fusion gene downstream of the 5HRE 
promoter. The resultant 5HREp-ODD-luc gene showed little leakage under normoxic 
conditions. Leakage from the conventional 5HREp-luc gene was 1.4 × 103 (arbitary units), on 
the other hand, that from the novel 5HREp-ODD-luc gene was just 1.5 × 101 (arbitary units), 
almost the same as the background level. Moreover, the oxygen-dependent destabilizing 
effect of the ODD domain contributed to an increase in the hypoxia-responsiveness to about 
4.7 × 104.  
The potential of hypoxia/HIF-1-dependent promoters in vivo has been proved through 
immunohistochemical analyses and optical imaging experiments. The human melanoma cell 
line, Be11, was stably transfected with a plasmid expressing a derivative of EGFP, d2EGFP, 
under the control of the 5HRE promoter, and transplanted into immunodeficient nude mice 
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HRE Basal Promoter Reporter Gene Induction Ratio References 
3 × mPGK-1 mPGK-1 CD2 1.4-1.9 
Dachs, 1997 3 × mPGK-1 minHSV TK CD2 2.2-2.33 
3 × mPGK-1 9-27 gene CD2 2.2-4.1 
mPGK-1 mPGK-1 hEPO 2.7 Rinsch, 1997 
hVEGF hVEGF luciferase 3.3-8.5 
Shibata, 1998 
hEPO SV40 luciferase 2-5 
5 × hVEGF hVEGF luciferase 20 
5 × hVEGF 
hVEGF+ 
minE1b 
luciferase  44 
3 × hENO SV40 luciferase 120 
Boast, 1999 
3 × hENO SV40 luciferase 63 
2 × mLDHA SV40 luciferase 81 
4 × mLDHA SV40 luciferase 65 
4 × hEPO SV40 luciferase 255 
3 × hENO SV40 luciferase  146 
3 × mPGK-1+
VEGF 3' UTR
SV40 luciferase 300 
mPGK-1 SV40 β-gal 8.5-50 Binley, 1999 
5 or 10 × hVEGF SV40 luciferase 54-57 
Shibata, 2000 
5 or 10 × hVEGF+ 
5' VEGF UTR 
SV40 luciferase 23-27 
5-10 × hVEGF+ 
5' VEGF UTR 
E1b luciferase 56-60 
5 × hVEGF+ 
5' VEGF UTR 
E1b luciferase 131 
5 × hVEGF+ 
5' VEGF UTR+ 
3' VEGF UTR 
E1b luciferase 193 
5 × hVEGF hCMV-mp luciferase 524 
5 × hVEGF hCMV-mp luciferase 47,000 Harada, 2007 
Table 1. Genetically engineered hypoxia-responsive promoters. 
(Liu et al., 2005). Resultant tumour xenografts showed heterogeneous, partition-dependent 
and weak green fluorescence. Immunohistochemical analyses confirmed that d2EGFP-
positive cells were located at the boundary between well-oxygenated viable regions and 
necrotic regions, which were stained with a hypoxia marker, pimonidazole (Raleigh et al., 
1998). When human cervical cancer cells, HeLa cells, transfected with the 5HREp-luc or 
5HREp-ODD-luc gene were transplanted into nude mice, the resultant xenografts showed 
intense bioluminescence after the tumour-bearing leg was ligated and the blood flow to the 
xenograft decreased (Harada, Kizaka-Kondoh, & Hiraoka, 2005; Harada et al., 2007).  
4.2 Hypoxia-targeted gene-directed enzyme/prodrug therapy using a HIF-1-dependent 
promoter  
To exploit tumour hypoxia/HIF-1 active cells as a tumour-specific therapeutic target, 
several approaches have been examined including (1) hypoxia-targeting using 
hypoxia/HIF-1-responsive promoters combined with Gene-Directed Enzyme Prodrug 
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Therapies (GDEPT) (Greco, Marples, Joiner, & Scott, 2003; Liu, Harada, Ogura, Shibata, & 
Hiraoka, 2007; Ogura et al., 2005; Patterson et al., 2002; Shibata, Giaccia, & Brown, 2002), and 
(2) hypoxia-specific replication of adenovirus (Hernandez-Alcoceba, Pihalja, Qian, & Clarke, 
2002; Post & Van Meir, 2003) (Table 2). 
 
Delivery System Hypoxia-specific Strategy Result Reference 
NA (Transfected 
cancer cell line) 
GDEPT: 5 x VEGF-HRE-
containing promoter driven NTR 
gene expression in HT1080 cells 
and i.p. injection of the anticancer 
prodrug CB1954. 
Significant 
tumour growth 
delay 
Shibata, 2002 
NA (Transfected 
cancer cell line) 
GDEPT: 5 x VEGF-HRE-
containing promoter-driven HSV-
TK gene expression and i.p. 
injection of GCV 
Tumour growth 
suppression  
Ogura, 2005 
NA (Transfected 
cancer cell line) 
GDEPT: PGK-1 HRE/SV40 
chimeric promoter-driven P450R 
gene expression and i.p. injection 
of the 2-nitroimidazole 
bioreductive prodrug, RB6145 
Enhanced 
Radiotherapy 
Patterson, 2002 
Adenovirus GDEPT: optimized hypoxia 
response promoter using PGK-1 
HRE-driven human cytochrome 
P450 (CYP2B6) gene expression 
and i.p. injection of 
cyclophosphamide 
Delay in tumour 
growth 
Binley, 2003 
Adenovirus  3XHRE/5XERE-regulated E1A 
expression and hTERT (AdEHT2) 
or E2F-1 (AdEHE2F) promoter-
regulated E4 expression.  
Tumour growth 
suppression and 
regression 
Hernandez-
Alcoceba, 2002 
Adenovirus 
(intratumoural 
injection) 
GDEPT: 5 x VEGF-HRE-
containing promoter-driven 
bacterial cytosine deaminase 
(BCD) gene expression and i.p. 
injection of 5-FC. 
Tumour growth 
suppression and 
enhanced 
radiotherpy 
Liu, 2007 
Adenovirus human VEGF promoter-driven 
BAX gene expression 
induction of 
apoptosis and 
suppression of 
cell growth in 
vitro 
Kaliberov, 2002 
Table 2. Gene therapy strategies for tumour hypoxia examined so far.  
NA, not applicable; HSV-TK, the herpes simplex virus thymidine kinase; GCV, ganciclovir; 
GDEPT, Gene-Directed Enzyme Pordrug Therapy; NTR, nitroreductase; CRAD, 
conditionally replicative adenoviruses; ER, estrogen receptor; ERE, estrogen response 
element; hTERT, human telomerase reverse transcriptase; CD, cytosine deaminase; VEGF, 
Vascular Endthelial Growth Factor, 5-FU, 5-fluorouracil; 5-FC, 5-flucytosine; 
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4.2.1 Gene-directed enzyme prodrug therapy (GDEPT) with HIF-1-dependent 
promoters   
GDEPT involves the delivery to target cells of a foreign gene, which is non-toxic but 
activates prodrugs to toxic agents and induces anti-tumour effects (Fig. 3 Dachs, Dougherty, 
Stratford, & Chaplin, 1997; Greco et al., 2003). HIF-1 activity is detected at high levels in 
hypoxic tumour cells but generally not in normal tissues as mentioned above; therefore, 
HIF-1-dependent promoters provide a chance to accomplish tumour-specific GDEPT. The 
target-specificity and therapeutic effects of GDEPT with HIF-1-dpendent promoters have 
been examined in experimental tumour systems either by administering viral vectors 
(Binley et al., 2003; Liu et al., 2007) or by using unique tumour xenografts prepared by 
transplanting cancer cells which express a prodrug-activating enzyme under the control of a 
HIF-1-dependent promoter (Ogura et al., 2005; Patterson et al., 2002; Shibata et al., 2002). 
Examples of enzyme/prodrug combinations in GDEPT are the bacterial nitroreductase 
(NTR)/anticancer prodrug CB1954, the cytochrome P450 reductase (P450R)/RSU1069, the 
herpes simplex virus thymidine kinase (HSV-TK)/ganciclovir (GCV), and the bacterial 
cytosine deaminase (BCD)/anti-herpes viral agent 5- fluorocytosine (5-FC).  
 
 
Fig. 3. Concept of GDEPT targeting tumour hypoxia. 
Using HREs derived from the VEGF promoter, Shibata et al. generated vectors expressing a 
bacterial NTR gene in a HIF-1-dependent manner, and established stable transfectants of a 
human fibrosarcoma cell line, HT1080 (Shibata et al., 2002). Hypoxia-induced expression of 
the NTR protein correlated with increased sensitivity of HT1080 cells to the prodrug CB1954 
(Shibata et al., 2002). Growth delay assays with established tumour xenografts derived from 
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the same cells showed that significant antitumour effects were achieved with intraperitoneal 
injections of CB1954 (Shibata et al., 2002). In addition, respiration of 10% O2 increased the 
hypoxic fraction in the tumour xenograft in vivo and enhanced the antitumour effects 
(Shibata et al., 2002). 
A one-electron reductase, such as P450R, can be used for prodrug-activation. Patterson et al. 
reported that selective hypoxia-targeting could be accomplished by using an optimized 
PGK-1 HRE/SV40 chimeric promoter to regulate the expression of P450R. HT1080 cells 
stably transfected with the gene produced a 3.4-fold increase in P450R activity as a result of 
anoxic incubation, leading to a 30-fold enhancement of the cytotoxicity of the 2-
nitroimidazole bioreductive prodrug, RSU1069 (Patterson et al., 2002).  
As for HSV-TK/GCV gene therapy, Ogura et al. demonstrated that promoters containing 5 
copies of the VEGF HRE assured the expression of the HSV-TK gene in a HIF-active renal 
cell carcinoma, resulting in GCV-dependent tumour growth suppression (Ogura et al., 
2005). An important point of their study is that HIF-dependent HSV-TK/GCV gene therapy 
can target not only hypoxic but also normoxic renal cell carcinoma (RCC) cells because the 
VHL gene, which triggers the destruction of HIF-1α and HIF-2α during normoxia, is 
inactive in 33–57% of sporadic clear-cell RCCs, which accounts for 75% of RCCs.  
Binley et al. used an optimized hypoxia-responsive promoter (OBHRE) with the PGK-1 HRE 
and investigated hypoxia-targeted gene expression in vivo in the context of an adenoviral 
vector (Binley et al., 2003). The OBHRE promoter showed limited activity in the liver or 
spleen such that expression was 1000-fold lower than that driven by the strong CMV/IE 
promoter (Binley et al., 2003). However, in the context of the tumour microenvironment, the 
OBHRE promoter achieved expression levels comparable to that of the CMV/IE promoter. 
Moreover, they showed that an adenovirus expressing the human cytochrome P450 
(CYP2B6) regulated by the OBHRE promoter delays tumour growth in response to the 
prodrug cyclophosphamide (CPA) (Binley et al., 2003).  
As for CD/5-FC gene therapy, Liu et al. constructed an adenoviral vector in which the 5HRE 
promoter was responsible for the HIF-1-dependent expression of CD (Liu et al., 2007). 
Administration of the adenovirus resulted in the expression of CD in hypoxic regions of 
solid tumours, leading to 5- FC-dependent tumour growth suppression and enhancement of 
the therapeutic effect of radiation therapy (See Section 4.4 for details about the radio-
enhancing effect).  
In general, GDEPT is thought to have two advantages: amplification of its therapeutic effect 
and a bystander therapeutic effect. The former is due to the ability of each prodrug-
activating enzyme to activate a number of prodrug molecules. The latter advantage results 
from an extension of the killing effects of the activated/converted drug to surrounding 
cancer cells, which don’t express the therapeutic gene and don’t convert the prodrug to the 
active anticancer drug. Therefore, even if systemic delivery of the therapeutic genes is not 
effective Fig. 3, tumour eradication may still be achieved. 
4.2.2 Other gene therapy strategies targeting tumour hypoixia   
4.2.2.1 Gene therapy using a cytotoxic gene and HIF-1-dependent promoter 
An alternative GDEPT uses cytotoxic proteins instead of prodrug-activating enzymes 
expressed in a HIF-1-dependent manner (Table 2). Kaliberov et al. prepared an adenovirus, 
AdVEGFBAX, which expressed an inducer of apoptosis, BAX, under the control of a VEGF 
promoter (Kaliberov et al., 2002). They confirmed the potential therapeutic application of 
VEGF promoter–driven cancer-specific expression of the pro-apoptotic Bax gene.  
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4.2.2.2 Gene therapy using a hypoxia/HIF-dependent oncolytic adenovirus  
The lytic cycle of adenoviruses is known to result in the death of infected cells, and thus this 
property has been exploited as a therapeutic strategy against cancer. Post and Van Meir 
have developed a hypoxia/HIF-dependent replicative adenovirus (HYPR-Ad) that exhibits 
HIF-1-dependent E1A expression and conditional cytolysis of hypoxic cells but not 
normoxic cells (Post & Van Meir, 2003). This is the first evidence that an attenuated oncolytic 
adenovirus that selectively lyses hypoxic tumour cells can be generated. 
4.3 Side effect of hypoxia-targeting gene therapies   
To measure the damage to normal tissue after gene therapy targeting tumour hypoxia, 
Binley et al. evaluated the activity of lactate dehydrogenase (LDH) as an indicator of liver 
dysfunction after their hypoxia-responsive thymidine kinase/ganciclovir (TK/GCV) suicide 
gene therapy (Binley et al., 2003). Hypoxia-dependent TK expression and subsequent GCV 
treatment caused no irregularity in LDH levels. On the other hand, constitutive TK 
expression from a CMV promoter and GCV treatment significantly elevated LDH levels in 
mice. These results suggest that a hypoxia-responsive promoter would facilitate target 
specificity and so reduce the side effects on well-oxygenated normal tissues, meaning an 
increased therapeutic window for cytotoxic cancer gene therapies.  
Liu et al observed no obvious side effects after hypoxia-targeting gene therapy with a 5HRE 
promoter-mediated BCD/5-FC strategy (Liu et al., 2007). On the other hand, after the 
Ad/EFp-BCD/5-FC treatment, which constitutively expresses BCD regardless of 
surrounding oxygen conditions, they observed significant weight loss and severe diarrhea 
(Liu et al., 2007). These results strengthen the argument that we can exploit tumour hypoxia 
as a tumour-specific target of cancer gene therapy, and that hypoxia/HIF-1-dependent 
therapeutic gene expression helps to avoid side effects in normal tissues. 
4.4 Improvement of the effect of radiotherapy by hypoxia/HIF-1-targeting gene 
therapies 
As tumour hypoxia and HIF-1 activity are responsible for tumour radioresistance 
(Aebersold et al., 2001; Harada et al., 2009; Irie et al., 2004; Ishikawa et al., 2004; Moeller et 
al., 2004; Moeller et al., 2005; X. Zhang et al., 2004), the specific targeting of tumour hypoxia 
and/or HIF-1 activity by gene therapy strategies may improve the efficacy of radiotherapy. 
Actually, Patterson et al. demonstrated that the therapeutic effect of radiation can be 
enhanced by a hypoxia-targeting gene therapy strategy (Patterson et al., 2002). They 
transfected HT1080 cells with a hypoxia-regulated expression vector encoding the human 
P450 reductase (HRE-P450R). Xenografts of HRE-P450R and empty vector transfectants had 
comparable hypoxic fractions and were refractive to a single dose of radiotherapy of up to 
15 Gy. However, combining a prodrug RSU1069 with a reduced dose of radiotherapy (10 
Gy) cured 50% of mice bearing HRE-P450R xenografts by 100 days after the treatment. On 
the other hand, one hundred percent mortality was observed by day 44 in the empty vector 
control xenografts treated using the same protocol.  
Liu et al. treated HeLa tumour xenografts with adenovirus-mediated hypoxia-targeting 
cytosine deaminase gene therapy (Ad/5HREp-BCD/5-FC) and/or radiotherapy (IR), and 
carried out growth delay assays (Liu et al., 2007). They intentionally chose a low dose of 
Ad/5HREp-BCD/5-FC, which had minimal effects on the tumour growth rate compared to 
that after sham-treatment. Combined with IR, the gene therapy strikingly suppressed 
tumour growth as compared to radiotherapy alone. The period taken for tumour growth to 
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increase two-fold from the initial volume (tumour growth doubling time: TGDT) was 13.2 ± 
5.6 days after gene therapy alone, which is not significantly longer than that after sham-
treatment (8.2 ± 3.1 days). On the other hand, the combination of gene therapy with 
radiotherapy prolonged the TGDT to 47.2 ± 16.8 days, which was about 2.4-fold longer than 
that after radiotherapy alone (19.4 ± 4.8 days). Similar results were observed after 
fractionated irradiation (3 Gy × 5 fractions). The TGDT after gene therapy alone was 13.0 ± 
4.4 days, which is not significantly longer than that after sham treatment (9.8 ± 5.8 days). On 
the other hand, the TGDT after the fractionated radiotherapy was 17.0 ± 3.7 days, which was 
significantly delayed by the combination with the gene therapy to 43.3 ± 23.8 days. These 
results also lead to a conclusion that hypoxia-targeting gene therapy combined with 
radiotherapy is a promising approach to cancer treatment. 
5. Conclusion 
Cancer cells under hypoxic conditions/HIF-1-active cancer cells have been recognized as 
crucial and excellent targets for cancer therapy not only because they mediate tumour 
malignancy and resistance to conventional treatments but also because they are only seen in 
malignant tumours, not in normal tissues. Several approaches have been used to target these 
cell populations; hypoxia-targeting using hypoxia-responsive promoters combined with 
GDEPT, and hypoxia-specific replication of adenovirus as well as hypoxic cytotoxins and 
HIF-1 inhibitors. Hypoxia/HIF-1-targeting gene therapy is a promising tumour-specific 
approach with few side effects in normal tissues, and has the potential to enhance the effect 
of radiation therapy. Some approaches are now in clinical trials and are expected to lead to 
breakthroughs in cancer therapy. 
6. Acknowledgements 
This study was supported by the “Funding Program for Next Generation World-Leading 
Researchers” from the Japan Society for the Promotion of Science (JSPS), by the “Program 
for the Promotion of Fundamental Studies in Health Science” from the National Institute of 
Biomedical Innovation (NIBIO), Japan, by Grants-in-aid for Scientific Research for Young 
Scientists (B) from the Ministry of Education, Culture, Sports, Science and Technology 
(MEXT), Japan, and by the Sagawa Foundation for the Promotion of Cancer Research.  
7. References 
Aebersold, D. M., Burri, P., Beer, K. T., Laissue, J., Djonov, V., Greiner, R. H., et al. (2001). 
Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic 
parameter in the radiotherapy of oropharyngeal cancer. Cancer Res, 61(7), 2911-
2916. 
Batchelder, R. M., Wilson, W. R., Hay, M. P., & Denny, W. A. (1996). Oxygen dependence of 
the cytotoxicity of the enediyne anti-tumour antibiotic esperamicin A1. Br J Cancer 
Suppl, 27, S52-56. 
Berra, E., Roux, D., Richard, D. E., & Pouyssegur, J. (2001). Hypoxia-inducible factor-1 alpha 
(HIF-1 alpha) escapes O(2)-driven proteasomal degradation irrespective of its 
subcellular localization: nucleus or cytoplasm. EMBO Rep, 2(7), 615-620. 
Bindra, R. S., Crosby, M. E., & Glazer, P. M. (2007). Regulation of DNA repair in hypoxic 
cancer cells. Cancer Metastasis Rev, 26(2), 249-260. 
www.intechopen.com
 Gene Therapy Strategy for Tumour Hypoxia 
 
197 
Binley, K., Askham, Z., Martin, L., Spearman, H., Day, D., Kingsman, S., et al. (2003). 
Hypoxia-mediated tumour targeting. Gene Ther, 10(7), 540-549. 
Binley, K., Iqball, S., Kingsman, A., Kingsman, S., & Naylor, S. (1999). An adenoviral vector 
regulated by hypoxia for the treatment of ischaemic disease and cancer. Gene Ther, 
6(10), 1721-1727. 
Boast, K., Binley, K., Iqball, S., Price, T., Spearman, H., Kingsman, S., et al. (1999). 
Characterization of physiologically regulated vectors for the treatment of ischemic 
disease. Hum Gene Ther, 10(13), 2197-2208. 
Brizel, D. M., Scully, S. P., Harrelson, J. M., Layfield, L. J., Bean, J. M., Prosnitz, L. R., et al. 
(1996). Tumour oxygenation predicts for the likelihood of distant metastases in 
human soft tissue sarcoma. Cancer Res, 56(5), 941-943. 
Brown, J. M. (1979). Evidence for acutely hypoxic cells in mouse tumours, and a possible 
mechanism of reoxygenation. Br J Radiol, 52(620), 650-656. 
Brown, J. M., & Wilson, W. R. (2004). Exploiting tumour hypoxia in cancer treatment. Nat 
Rev Cancer, 4(6), 437-447. 
Chan, D. A., & Giaccia, A. J. (2007). Hypoxia, gene expression, and metastasis. Cancer 
Metastasis Rev, 26(2), 333-339. 
Chan, N., Koritzinsky, M., Zhao, H., Bindra, R., Glazer, P. M., Powell, S., et al. (2008). 
Chronic hypoxia decreases synthesis of homologous recombination proteins to 
offset chemoresistance and radioresistance. Cancer Res, 68(2), 605-614. 
Comerford, K. M., Wallace, T. J., Karhausen, J., Louis, N. A., Montalto, M. C., & Colgan, S. P. 
(2002). Hypoxia-inducible factor-1-dependent regulation of the multidrug 
resistance (MDR1) gene. Cancer Res, 62(12), 3387-3394. 
Dachs, G. U., Dougherty, G. J., Stratford, I. J., & Chaplin, D. J. (1997). Targeting gene therapy 
to cancer: a review. Oncol Res, 9(6-7), 313-325. 
Dachs, G. U., Patterson, A. V., Firth, J. D., Ratcliffe, P. J., Townsend, K. M., Stratford, I. J., et 
al. (1997). Targeting gene expression to hypoxic tumour cells. Nat Med, 3(5), 515-
520. 
Durand, R. E. (1994). The influence of microenvironmental factors during cancer therapy. In 
Vivo, 8(5), 691-702. 
Erler, J. T., Bennewith, K. L., Nicolau, M., Dornhofer, N., Kong, C., Le, Q. T., et al. (2006). 
Lysyl oxidase is essential for hypoxia-induced metastasis. Nature, 440(7088), 1222-
1226. 
Folkman, J. (1971). Tumour angiogenesis: therapeutic implications. N Engl J Med, 285(21), 
1182-1186. 
Forsythe, J. A., Jiang, B. H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., et al. (1996). 
Activation of vascular endothelial growth factor gene transcription by hypoxia-
inducible factor 1. Mol Cell Biol, 16(9), 4604-4613. 
Fukuda, R., Zhang, H., Kim, J. W., Shimoda, L., Dang, C. V., & Semenza, G. L. (2007). HIF-1 
regulates cytochrome oxidase subunits to optimize efficiency of respiration in 
hypoxic cells. Cell, 129(1), 111-122. 
Greco, O., Marples, B., Joiner, M. C., & Scott, S. D. (2003). How to overcome (and exploit) 
tumour hypoxia for targeted gene therapy. J Cell Physiol, 197(3), 312-325. 
Hall, E. J. (Ed.). (1994). Radiobiology for the Radiologists, Fourth Edition. Philadelphia: J.B. 
Lippincott Company. 
Hanahan, D., & Weinberg, R. A. (2000). The hallmarks of cancer. Cell, 100(1), 57-70. 
Harada, H., & Hiraoka, M. (2010). Hypoxia-inducible factor 1 in tumour radioresistance. 
Current Signal Transduction Therapy, 5, 188-196. 
www.intechopen.com
 Targets in Gene Therapy 
 
198 
Harada, H., Itasaka, S., Zhu, Y., Zeng, L., Xie, X., Morinibu, A., et al. (2009). Treatment 
regimen determines whether an HIF-1 inhibitor enhances or inhibits the effect of 
radiation therapy. Br J Cancer, 100(5), 747-757. 
Harada, H., Kizaka-Kondoh, S., & Hiraoka, M. (2005). Optical imaging of tumour hypoxia 
and evaluation of efficacy of a hypoxia-targeting drug in living animals. Mol 
Imaging, 4(3), 182-193. 
Harada, H., Kizaka-Kondoh, S., Itasaka, S., Shibuya, K., Morinibu, A., Shinomiya, K., et al. 
(2007). The combination of hypoxia-response enhancers and an oxygen-dependent 
proteolytic motif enables real-time imaging of absolute HIF-1 activity in tumour 
xenografts. Biochem Biophys Res Commun, 360(4), 791-796. 
Harris, A. L. (2002). Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer, 
2(1), 38-47. 
Hernandez-Alcoceba, R., Pihalja, M., Qian, D., & Clarke, M. F. (2002). New oncolytic 
adenoviruses with hypoxia- and estrogen receptor-regulated replication. Hum Gene 
Ther, 13(14), 1737-1750. 
Hicks, K. O., Pruijn, F. B., Secomb, T. W., Hay, M. P., Hsu, R., Brown, J. M., et al. (2006). Use 
of three-dimensional tissue cultures to model extravascular transport and predict in 
vivo activity of hypoxia-targeted anticancer drugs. J Natl Cancer Inst, 98(16), 1118-
1128. 
Hirota, K., & Semenza, G. L. (2005). Regulation of hypoxia-inducible factor 1 by prolyl and 
asparaginyl hydroxylases. Biochem Biophys Res Commun, 338(1), 610-616. 
Irie, N., Matsuo, T., & Nagata, I. (2004). Protocol of radiotherapy for glioblastoma according 
to the expression of HIF-1. Brain Tumour Pathol, 21(1), 1-6. 
Ishikawa, H., Sakurai, H., Hasegawa, M., Mitsuhashi, N., Takahashi, M., Masuda, N., et al. 
(2004). Expression of hypoxic-inducible factor 1alpha predicts metastasis-free 
survival after radiation therapy alone in stage IIIB cervical squamous cell 
carcinoma. Int J Radiat Oncol Biol Phys, 60(2), 513-521. 
Jaakkola, P., Mole, D. R., Tian, Y. M., Wilson, M. I., Gielbert, J., Gaskell, S. J., et al. (2001). 
Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-
regulated prolyl hydroxylation. Science, 292(5516), 468-472. 
Kaliberov, S. A., Buchsbaum, D. J., Gillespie, G. Y., Curiel, D. T., Arafat, W. O., Carpenter, 
M., et al. (2002). Adenovirus-mediated transfer of BAX driven by the vascular 
endothelial growth factor promoter induces apoptosis in lung cancer cells. Mol 
Ther, 6(2), 190-198. 
Kim, J. W., Gao, P., & Dang, C. V. (2007). Effects of hypoxia on tumour metabolism. Cancer 
Metastasis Rev, 26(2), 291-298. 
Kizaka-Kondoh, S., Inoue, M., Harada, H., & Hiraoka, M. (2003). Tumour hypoxia: a target 
for selective cancer therapy. Cancer Sci, 94(12), 1021-1028. 
Liu, J., Harada, H., Ogura, M., Shibata, T., & Hiraoka, M. (2007). Adenovirus-mediated 
hypoxia-targeting cytosine deaminase gene therapy enhances radiotherapy in 
tumour xenografts. Br J Cancer, 96(12), 1871-1878. 
Liu, J., Qu, R., Ogura, M., Shibata, T., Harada, H., & Hiraoka, M. (2005). Real-time imaging 
of hypoxia-inducible factor-1 activity in tumour xenografts. J Radiat Res (Tokyo), 
46(1), 93-102. 
Mahon, P. C., Hirota, K., & Semenza, G. L. (2001). FIH-1: a novel protein that interacts with 
HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes 
Dev, 15(20), 2675-2686. 
www.intechopen.com
 Gene Therapy Strategy for Tumour Hypoxia 
 
199 
Maxwell, P. H., Wiesener, M. S., Chang, G. W., Clifford, S. C., Vaux, E. C., Cockman, M. E., 
et al. (1999). The tumour suppressor protein VHL targets hypoxia-inducible factors 
for oxygen-dependent proteolysis. Nature, 399(6733), 271-275. 
Moeller, B. J., Cao, Y., Li, C. Y., & Dewhirst, M. W. (2004). Radiation activates HIF-1 to 
regulate vascular radiosensitivity in tumours: role of reoxygenation, free radicals, 
and stress granules. Cancer Cell, 5(5), 429-441. 
Moeller, B. J., Dreher, M. R., Rabbani, Z. N., Schroeder, T., Cao, Y., Li, C. Y., et al. (2005). 
Pleiotropic effects of HIF-1 blockade on tumour radiosensitivity. Cancer Cell, 8(2), 
99-110. 
Ogura, M., Shibata, T., Yi, J., Liu, J., Qu, R., Harada, H., et al. (2005). A tumour-specific gene 
therapy strategy targeting dysregulation of the VHL/HIF pathway in renal cell 
carcinomas. Cancer Sci, 96(5), 288-294. 
Patterson, A. V., Williams, K. J., Cowen, R. L., Jaffar, M., Telfer, B. A., Saunders, M., et al. 
(2002). Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of 
radiation-resistant solid tumours. Gene Ther, 9(14), 946-954. 
Pennacchietti, S., Michieli, P., Galluzzo, M., Mazzone, M., Giordano, S., & Comoglio, P. M. 
(2003). Hypoxia promotes invasive growth by transcriptional activation of the met 
protooncogene. Cancer Cell, 3(4), 347-361. 
Post, D. E., & Van Meir, E. G. (2003). A novel hypoxia-inducible factor (HIF) activated 
oncolytic adenovirus for cancer therapy. Oncogene, 22(14), 2065-2072. 
Raleigh, J. A., Calkins-Adams, D. P., Rinker, L. H., Ballenger, C. A., Weissler, M. C., Fowler, 
W. C., Jr., et al. (1998). Hypoxia and vascular endothelial growth factor expression 
in human squamous cell carcinomas using pimonidazole as a hypoxia marker. 
Cancer Res, 58(17), 3765-3768. 
Rinsch, C., Regulier, E., Deglon, N., Dalle, B., Beuzard, Y., & Aebischer, P. (1997). A gene 
therapy approach to regulated delivery of erythropoietin as a function of oxygen 
tension. Hum Gene Ther, 8(16), 1881-1889. 
Rofstad, E. K. (2000). Microenvironment-induced cancer metastasis. Int J Radiat Biol, 76(5), 
589-605. 
Semenza, G. L. (2001). HIF-1, O(2), and the 3 PHDs: how animal cells signal hypoxia to the 
nucleus. Cell, 107(1), 1-3. 
Semenza, G. L. (2003). Targeting HIF-1 for cancer therapy. Nat Rev Cancer, 3(10), 721-732. 
Semenza, G. L. (2007). Oxygen-dependent regulation of mitochondrial respiration by 
hypoxia-inducible factor 1. Biochem J, 405(1), 1-9. 
Semenza, G. L. (2008). Mitochondrial autophagy: life and breath of the cell. Autophagy, 4(4), 
534-536. 
Semenza, G. L. (2009). Regulation of cancer cell metabolism by hypoxia-inducible factor 1. 
Semin Cancer Biol, 19(1), 12-16. 
Shibata, T., Akiyama, N., Noda, M., Sasai, K., & Hiraoka, M. (1998). Enhancement of gene 
expression under hypoxic conditions using fragments of the human vascular 
endothelial growth factor and the erythropoietin genes. Int J Radiat Oncol Biol Phys, 
42(4), 913-916. 
Shibata, T., Giaccia, A. J., & Brown, J. M. (2000). Development of a hypoxia-responsive 
vector for tumour-specific gene therapy. Gene Ther, 7(6), 493-498. 
Shibata, T., Giaccia, A. J., & Brown, J. M. (2002). Hypoxia-inducible regulation of a prodrug-
activating enzyme for tumour-specific gene therapy. Neoplasia, 4(1), 40-48. 
Tannock, I. F. (1968). The relation between cell proliferation and the vascular system in a 
transplanted mouse mammary tumour. Br J Cancer, 22(2), 258-273. 
www.intechopen.com
 Targets in Gene Therapy 
 
200 
Tannock, I. F. (1998). Conventional cancer therapy: promise broken or promise delayed? 
Lancet, 351 Suppl 2, SII9-16. 
Teicher, B. A. (1994). Hypoxia and drug resistance. Cancer Metastasis Rev, 13(2), 139-168. 
Teicher, B. A., Lazo, J. S., & Sartorelli, A. C. (1981). Classification of antineoplastic agents by 
their selective toxicities toward oxygenated and hypoxic tumour cells. Cancer Res, 
41(1), 73-81. 
Thomlinson, R. H., & Gray, L. H. (1955). The histological structure of some human lung 
cancers and the possible implications for radiotherapy. Br J Cancer, 9(4), 539-549. 
Vaupel, P., Kallinowski, F., & Okunieff, P. (1989). Blood flow, oxygen and nutrient supply, 
and metabolic microenvironment of human tumours: a review. Cancer Res, 49(23), 
6449-6465. 
Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995). Hypoxia-inducible factor 1 is a 
basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl 
Acad Sci U S A, 92(12), 5510-5514. 
Wartenberg, M., Ling, F. C., Muschen, M., Klein, F., Acker, H., Gassmann, M., et al. (2003). 
Regulation of the multidrug resistance transporter P-glycoprotein in multicellular 
tumour spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species. 
FASEB J, 17(3), 503-505. 
Wood, S. M., Wiesener, M. S., Yeates, K. M., Okada, N., Pugh, C. W., Maxwell, P. H., et al. 
(1998). Selection and analysis of a mutant cell line defective in the hypoxia-
inducible factor-1 alpha-subunit (HIF-1alpha). Characterization of hif-1alpha-
dependent and -independent hypoxia-inducible gene expression. J Biol Chem, 
273(14), 8360-8368. 
Yang, M. H., Wu, M. Z., Chiou, S. H., Chen, P. M., Chang, S. Y., Liu, C. J., et al. (2008). Direct 
regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol, 10(3), 295-
305. 
Zeng, L., Ou, G., Itasaka, S., Harada, H., Xie, X., Shibuya, K., et al. (2008). TS-1 enhances the 
effect of radiotherapy by suppressing radiation-induced hypoxia-inducible factor-1 
activation and inducing endothelial cell apoptosis. Cancer Sci, 99(11), 2327-2335. 
Zhang, H., Bosch-Marce, M., Shimoda, L. A., Tan, Y. S., Baek, J. H., Wesley, J. B., et al. (2008). 
Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to 
hypoxia. J Biol Chem, 283(16), 10892-10903. 
Zhang, X., Kon, T., Wang, H., Li, F., Huang, Q., Rabbani, Z. N., et al. (2004). Enhancement of 
hypoxia-induced tumour cell death in vitro and radiation therapy in vivo by use of 
small interfering RNA targeted to hypoxia-inducible factor-1alpha. Cancer Res, 
64(22), 8139-8142. 
www.intechopen.com
Targets in Gene Therapy
Edited by Prof. Yongping You
ISBN 978-953-307-540-2
Hard cover, 436 pages
Publisher InTech
Published online 23, August, 2011
Published in print edition August, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
This book aims at providing an up-to-date report to cover key aspects of existing problems in the emerging
field of targets in gene therapy. With the contributions in various disciplines of gene therapy, the book brings
together major approaches: Target Strategy in Gene Therapy, Gene Therapy of Cancer and Gene Therapy of
Other Diseases. This source enables clinicians and researchers to select and effectively utilize new
translational approaches in gene therapy and analyze the developments in target strategy in gene therapy.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Hiroshi Harada (2011). Gene Therapy Strategy for Tumour Hypoxia, Targets in Gene Therapy, Prof. Yongping
You (Ed.), ISBN: 978-953-307-540-2, InTech, Available from: http://www.intechopen.com/books/targets-in-
gene-therapy/gene-therapy-strategy-for-tumour-hypoxia
© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed
under the terms of the Creative Commons Attribution-NonCommercial-
ShareAlike-3.0 License, which permits use, distribution and reproduction for
non-commercial purposes, provided the original is properly cited and
derivative works building on this content are distributed under the same
license.
